Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Scientific Reports|September 15, 2016
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup AnalysisRaphaela Lohaus, Jonathan Michel, Katharina Mayer, et al.
Angewandte Chemie (International Ed. in English)|October 6, 2021
Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACsJaeki Min, Anand Mayasundari, Fatemeh Keramatnia, et al.
Thrombosis and Haemostasis|August 8, 2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stentsYukinori Harada, Jonathan Michel, Raphaela Lohaus, et al.
Blood|June 10, 2021
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemiaYunchao Chang, Jaeki Min, Jamie A Jarusiewicz, et al.
Plos One|August 21, 2008
Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation studyPatrick Linsel-Nitschke, Anika Götz, Jeanette Erdmann, et al.
Circulation|March 26, 2008
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery diseaseHeribert Schunkert, Anika Götz, Peter Braund, et al.
The New England Journal of Medicine|July 20, 2007
Genomewide association analysis of coronary artery diseaseNilesh J Samani, Jeanette Erdmann, Alistair S Hall, et al.
European Heart Journal|January 25, 2015
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stentingStefanie Schulz-Schüpke, Robert A Byrne, Jurrien M Ten Berg, et al.
Nature Communications|January 16, 2024
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell linesGisele Nishiguchi, Lauren G Mascibroda, Sarah M Young, et al.
The New England Journal of Medicine|September 3, 2019
Ticagrelor or Prasugrel in Patients with Acute Coronary SyndromesStefanie Schüpke, Franz-Josef Neumann, Maurizio Menichelli, et al.
Pageof 17